INTRODUCTION
The traditional vaccine against whooping cough composed of whole killed Bordetella pertussis bacterial cells has been successful in controlling pertussis in most developed countries."2 However, concerns over its reactogenicity have motivated the development of safe and effective acellular vaccines manufactured using highly purified antigens of B. pertussis. A range of acellular pertussis vaccines, comprising one or more of the antigens, detoxified pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN) and fimbriae (FIM) , have recently been evaluated in phase 3 clinical trials in Sweden, Italy, Germany and Senegal.3-8 When compared with the whole-cell vaccines, the incidence of adverse events associated ©0 1998 Blackwell Science Ltd with immunization of children with the acellular vaccines was considerably reduced.9 However, the estimated efficacy of the acellular vaccines did not rival that of most European whole-cell vaccines.237 Furthermore, it is not clear that the persistence of the immune response elicited with acellular vaccines will approach that generated by respiratory infection or immunization with the whole-cell vaccine and the mechanism(s) of protective immunity induced by pertussis vaccination is still poorly characterized.
Apart from preliminary evidence from a household contact study,'0 the clinical trials have failed to show a clear correlation between levels of serum antibodies to B. pertussis antigens and protection.3-91 While circulating antibodies are known to play a role in both toxin neutralization and prevention of bacterial attachment to respiratory epithelial cells, evidence is emerging that humoral immunity alone may not be sufficient to confer protection against B. pertussis infection.12-14 It is now accepted that B. pertussis is not exclusively an extracellular pathogen, but that it has the ability to invade and survive within mammalian cells, including alveolar macrophages, 15"16 suggesting that cell-mediated immunity may be required to completely eliminate invasive bacteria. Studies in a murine respiratory infection model have demonstrated that the adoptive transfer of CD4+ T cells from immune mice can confer protection to nude or immunosuppressed recipient mice against aerosol challenge with live B. pertussis in the absence of a detectable serum antibody response.'3 These protective T cells 1 were shown to secrete high levels of interleukin-2 (IL-2) and interferon-y (IFN-y), but not IL-4 or IL-5, a cytokine profile characteristic of T helper 1 (Thl) cells. 13 '14,"7 Furthermore, immunization of mice with a whole cell pertussis vaccine generated Thl responses and moderate antibody levels14"17"18 and conferred a high level of protection against respiratory infection.14 In contrast, an acellular vaccine induced Th2/ThO cells and strong antibody response, and did not confer the same level of protection in the murine respiratory challenge model. 14.17 We have already reported that B. pertussis infection in children is associated with preferential activation of type 1 106/ml with heat-killed bacteria (I06-I07 bacteria/ml), FHA (1-10 I tg/ml), heat inactivated PT (0 1-5 0 ,ug/ml), PRN (1-10pg/ml) for 6 days at 370 in a humidified CO2 incubator. Control stimuli included medium alone or anti-CD3 (OKT3, 2 0 ,ug/ml) and phorbol 12-myristate 13-acetate (PMA) (25 ng/ml). Because of limitations on cell yield from the blood volumes available, not all PBMC preparations were tested against the full range of antigens. Proliferation was assessed by [3H]thymidine incorporation after 6 days of culture, as described. '9 Cytokine analysis was performed on supernatants of PBMC stimulated as described for the proliferation assay. Supernatants were removed after 72 hr and the levels of IFN-y, and IL-5 measured by immunoassays, as described.'9 The limits of sensitivity of the assays were 0 25 U/ml for IFN-'y and 15 pg/ml for IL-5. In certain experiments the concentrations of IL-2 were also determined using the cytotoxic T lymphocyte line (CTLL) bioassay ' Analysis of T-cell responses in un-vaccinated children enabled the discrimination between B. pertussis antigen-specific responses induced by vaccination compared with that present in a 'naive' population prior to vaccination. As we have previously reported,'9 PBMC from a proportion of unvaccinated children did display positive B. pertussis-specific T-cell responses, but this was restricted to IFN-y production ( Figs  1-3 ). IFN-y levels greater than 0 5 U/ml were detected in 1998 Blackwell Science Ltd, Immunology, 93, 1-10 culture supernatants of PBMC from 29% of children examined in response to at least two of the B. pertussis antigens: PT, FHA and PRN. Polyclonal activation with anti-CD3 and PMA revealed that PBMC from all naive children examined were capable of secreting high levels of IFN-y (. 50 U/ml) and IL-5 (. 1000 pg/ml) (data not shown). IL-5 was chosen as a marker of Th2 activation as IL-4 is difficult to measure in culture supernatants, especially with PBMC from children.
Selective induction of type 1 T cells with whole cell pertussis vaccines Twenty-five 12-13-month-old children that had received three doses of the W/M Pw vaccine at 2, 3 and 4 months, as part of a clinical trial in Oxford, UK, were assessed 8-9 months after vaccination. Four 1-2-year-old children that had received primary vaccination with three doses of the W/M Pw at 3, 5 and 10 months as part of the routine immunization programme in Norway were tested 2-8 months post vaccination. Moderate to high levels of IFN-y was detected in supernatants of PBMC following in vitro stimulation with PT (66% samples tested), FHA (62%) and PRN (72%) (Figs 1-3) . Furthermore high levels of antigen-specific IFN-y production was detected in 78% of children following stimulation of PBMC with killed B. pertussis, but not with medium only (data not shown). Positive IFN-y responses to at least two of the B. pertussis antigens was detected in 90% of the vaccinated children examined. In contrast, IL-5 was undetectable following stimulation of the same PBMC preparations with any of the B. pertussis antigen preparations tested (Figs 1-3 yield from small blood volumes available), antigen-specific proliferation and IL-2 production was also assessed in eight children immunized with the SB Pa3 and in three naive children on the same days. PBMC from children immunized with the SB Pa3 proliferated and secreted IL-2 when stimulated in vitro with inactivated PT, FHA, PRN and killed B. pertussis (Fig. 5) . Although proliferation and low levels of IL-2 was detected in response to killed B. pertussis in one of the naive children, the response to the purified antigens were significantly greater in the immunized children (Fig. 5 ). The CLL Pa5 also induced T cells with a heterogenous cytokine profile. IFN-y and IL-5 production was detected in antigen-stimulated PBMC from 17, 29 and 29% of children examined in response to PT, FHA and PRN, respectively. Thl-like response, with the production of IFN-y, but not IL-5, were detected in 33, 29 and 17% of vaccinees in response to PT, FHA and PRN, respectively. Th2-like responses (IL-5 only) were detected in 4% and 12% of vaccinees following in vitro stimulation of PBMC with PT and PRN, but none with FHA (Figs 1-3) . Positive T-cell responses to at least two of the B. pertussis antigens were detected in 54% of vaccinated children. Similar patterns of cytokine secretion were detected in antigen-stimulated PBMC from recently vaccinated children and children immunized 2-4 years earlier.
Although the numbers of children examined were too small to detect statistically significant differences, the CB Pa3 prepared with genetically detoxified PT combined with FHA and PRN, appeared to induce T-cell responses which were more polarized to the Thl subtype. Positive IFN-y responses were detected in 71% of vaccinated children, whereas a Th2 cytokine pattern (IL-5 only) was not detected in response to any of the antigens in any of the PBMC preparations examined. PBMC from 43, 57 and 43% and vaccines secreted IFN-y, but undetectable IL-5 following in vitro stimulation with PT, FHA and PRN, respectively. A mixed Thl/Th2 cytokine profile characterized by the detection of significant levels of IFN-'y and IL-5 was observed in 7, 7 and 21% of vaccinees in responses to PT, FHA and PRN, respectively (Figs 1-3) . Positive T-cell responses to at least two of the B. pertussis antigens were detected in 64% of vaccinated children.
Late post vaccination blood samples were also obtained from 31 children 2-4 years after immunization with three doses of SB Pa2 (Stockholm efficacy trial 1992-95) and an additional 12 children (1-2 years old) that had been immunized with the SB Pa2 (Stockholm efficacy trial 1993-96) were assessed 8-12 months after vaccination. The main feature of the T-cell response in children immunized with the SB Pa2 was the low or undetectable levels of IL-5. Low but significant levels (greater than twice the sensitivity of the assay) of IFN-'y were detected in 50 and 54% of PBMC preparations in response to PT and FHA and an additional 12% also secreted IL-5 following stimulation with PT (Figs 1-2) . However, the levels of IL-5 were below the limit of detection in the supernatants (Fig. 4a) . In a second study, 36 children who had received W/M Pw as part of the routine diphtheria tetanus and pertussis (DTP) vaccination at 2, 3 and 4 months were examined 1 month after boosting with DT only or DTPa (CB Pa3 or PM Pa2) at 4 years of age. PBMC from the children which received DT vaccine only had detectable levels of IFN-y, but no IL-5, when stimulated in vitro with killed B. pertussis (Fig. 4b) . In contrast, PBMC from a proportion of the children that received the booster dose with the acellular vaccines produced IFN-7y and low levels of IL-5 in response to purified B. pertussis antigens. By comparison with the study shown in Fig. 4a 
